[
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
[og_img]
https://www.investing.com/news/press-releases/new-fiveyear-sotyktu-deucravacitinib-data-show-consistent-safety-and-durable-response-rates-in-moderatetosevere-plaque-psoriasis-93CH-3871898
Investing.com
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Related articles
